However, increasingly, with the development of therapies such as venetoclax and BRAF inhibition which benefit patients with specific genetic abnormalities in MM, the future utility of genomics could include treatment selection as well as the assessment of MRD. Here, BRAF is linked to Miyoshi myopathy.